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Prenting Perinatal Transmission
Costs and Effectiveness
of a Recommended Intervention
of HIV

SYNOPSIS

Objective. To calculate the national costs of reducing pennatal transmission of
human immunodeficiency virus through counseling and voluntary testing of pregnant women and zidovudine treatment of infected women and their infants, as
recommended by the Public Health Service, and to compare these costs with
the savings from reducing the number of pediatric infections.
Method. The authors analyzed the estimated costs of the intervention and the
estimated cost savings from reducing the number of pediatric infections. The outcome measures are the number of infections prevented by the intervention and
the net cost (cost of intervention minus the savings from a reduced number of
pediatric HIV infections). The base model assumed that intervention participation
and outcomes would resemble those found in the AIDS Clinical Trials Group
Protocol 076. Assumptions were varied regarding matemal seroprevalence, participation by HIV-infected women, the proportion of infected women who
accepted and completed the treatment, and the efficacy of zidovudine to illustrate the effect of these assumptions on infections prevented and net cost.
Results. Without the intervention, a perinatal HIV transmission rate of 25%
would result in 1750 HIV-infected infants bom annually in the United States, with
lifetime medical-care costs estimated at $282 million. The cost of the intervention (counseling, testing, and zidovudine treatment) was estimated to be $67.6
million. In the base model, the intervention would prevent 656 pediatric HIV
infections with a medical care cost saving of $105.6 million. The net cost saving of
the intervention was $38.1 million.
Conclusion. Voluntary HIV screening of pregnant women and ziovudine treatment for infected women and their infants resulted in cost savings under most of
the assumptions used in this analysis. These results strongly support implementation of the Public Health Service recommendations for this intervention.

Address correspondence to Dr. Guinan,
Mail Stop D-01, Centersfor Disease
Control and Prevention, 1600 Clifton
Road N.E., Atlanta, GA 30333; tel. 404639-4475;fax 404-639-4463; e-mail

<meg3@epo.em.cdc.gov>.
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I n the United States, nearly all new human immunodeficiency virus
(HIV) infections in children are acquired through perinatal (mother-toinfant) transmission. Each year, approximately 7000 infants are born to
HIV-infected women in the United States.' Without intervention, an
estimated 15-3096 of these infants would become infected.2
In 1994, results of the AIDS Clinical Trial Group (ACTG) Protocol 076
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showed that treatment of infected pregnant women and
their infants with zidovudine (ZDV) reduced the rate of
perinatal HIV transmission from 25% to 8%.34 Following
these findings, the Public Health Service (PHS) issued recommendations for ZDV therapy to prevent perinatal HIV
transmission5 and for HIV counseling and voluntary testing
of pregnant women.6
The potential cost of HIV counseling and voluntary testing of pregnant women in the United States has not been
determined, nor has the cost-effectiveness of such screening
combined with recommended ZDV treatment for preventing
perinatal HIV transmission.4 Because medical care for HIV
infection is costly, savings resulting from HIV infections prevented can be substantial. The estimated annual costs for an
HIV-infected adult are $5,000 for persons who have not
developed AIDS and $35,000 for those with AIDS.7 For an
HIV-infected child, direct costs per year are $9,400 before
development of AIDS and $38,000 after AIDS.8
Data from various sources were used to calculate both
the intervention costs and the resulting pediatric medical
care cost savings. The intervention costs included HIV
counseling and voluntary testing services for pregnant
women, ZDV treatment prenatally and during labor and
delivery for those who are infected, ZDV treatment for their
infants, and recommended laboratory testing during ZDV
treatment.56 To determine the savings from preventing
pediatric infections, the costs associated with treatment for
infants perinatally infected without the intervention were
compared with treatment costs for infants who became
infected despite the intervention.

Methods
Actual costs for HIV counseling, testing, ZDV treatment, and medical treatment of infected infants were
included without regard to who would pay for them (societal perspective). The time horizon for the intervention
costs was one year. To determine the lifetime savings from
prevented pediatric infections, we included the present value
of medical care that would have been incurred in the future.
We did not consider the additional costs of treating HIVinfected women who would not have learned of their infection until later in the course of their illness, nor any additional benefits resulting from the intervention (for example,
reduced HIV transmission to sexual or needle-sharing partners of infected women).9"10
Intervention costs. The intervention was divided into two
cost components: (a) the direct costs associated with HIV
counseling and voluntary testing services for pregnant
women receiving first and second trimester prenatal care;
and (b) the costs associated with ZDV treatment (that is,
oral ZDV prenatally and intravenous ZDV during labor and
delivery for infected women, oral ZDV for HIV-exposed

newborns, and recommended laboratory testing during
ZDV therapy) (see Box).
336 Public Health

Reports

HIVcounseling and voluntary testing costs. The number of eligible women was defined as the number of pregnant women
of more than 13 weeks gestation'1 who receive prenatal
care.'2 We estimated this number by adding the fetal losses
and induced abortions occurring after 13 weeks gestation'3
to the number of annual live births in the United States.'2
This sum was then multiplied by the proportion of women
(.939) who receive first or second trimester prenatal care.'2
We made the following assumptions for the analysis: (a)
all pregnant women entering prenatal care during the first
Annual Cost Estimates of HIV Counseling and
Testing of All- Pregnant Women in the United States
and of Zidovudine (ZDV) Treatment of Infected
Women and Their Infants
Counseling and testing
Number of pregnancies' ...................
Number in prenatal careb ..................
Number counseled and testedc ..............
Number positive ........................
Number negatived ........................
(a)Total coste .........................

4,522,823
4,246,930
3,312,606
5,666
3,306,940
$65,068,921

ZDV treatrnent
Number of women eligible'................
Number accepting ZDV during pregnancy' .....
(b)Cost of ZDV during pregnancyh.........
(c)Cost of laboratory monitoring'..........
Number receiving ZDV during labor
and delivery ..........................
(d)Cost of ZDV during labor and delivery...
Number receiving neonatal ZDV.............
(e)Cost of neonatal ZDVk................
Total cost of ZDV regimen...............

2,849
$131,366
2,407
$40,486
$2,478,709

Total annual cost (a+b+c+d+e) ...........

$67,547,629

4,958
3,371
$1,858,466
$448,392

aIncluding pregnancies terminated or ending in fetal loss after the first trimester;
these women would be eligible for HIV counseling and testing (HIV CT)." '1'3
bAssumes all pregnant women entering prenatal care during the first two
trimesters are offered HIV CT.'2
'Assumes that pregnant women accept HIV CT in the same proportion as that
reported for other populations, 78%.2021
dAdjusted for the sensitivity and specificity of the HIV tests and recommended
test sequence;'7 assumes HIV seroprevalence of 1.7 per 1000 births.
'Cost for HIV CT: positive, $103; negative, $19.50.'7 (Adjusted as described in
paper.)
'Number positive adjusted for fetal losses and induced abortions occurring
after 13 weeks gestation.'3
'Assume 68% of infected pregnant women accept prenatal ZDV if offered.22
hZDV treatment cost-$551.25 per woman during pregnancy.
'Complete blood count at $21 per test (2 per woman and per child) and
chemistry profile at $35 per test (2 per woman)
ZDV treatment cost-$46. 1 per woman during labor and delivery; assumes
84.5% of women receiving ZDV during pregnancy also receive ZDV during
labor and delivery.4
kZDV treatment cost-$16.82 per newborn; assumes 71.4% of children born
to infected mothers receiving ZDV during pregnancy receive ZDV neonatally.4
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or second trimester would be offered HIV counseling and
testing; (b) women who had previously tested HIV seronegative would require retesting during each pregnancy; and (c)
the number of HIV-infected pregnant women who knew
their serostatus at entry into prenatal care would be small
compared with total births. Since empirical data were lacking, we also assumed that HIV screening would not affect
reproductive decision-making and that HIV seroprevalence
was the same for women accepting and those refusing HIV
tests.
HIV counseling and testing costs for seropositive
women differ from those for seronegative women. In addition, client-based14"5 counseling costs are greater for uninfected women at high risk (more extensive counseling) than
for those at low risk. To determine the cost of HIV counseling and testing of uninfected women, a weighted average
was calculated as follows-since 55% of U.S. women who
give birth reside in states with relatively high HIV seroprevalence rates (more than one HIV-infected pregnant
woman per 1000 live births),'6 we assumed that all seronegative pregnant women in these states would receive fulu
counseling with costs comparable to those found in publicly
funded clinics, or $33 per person.'7 This included the cost of
pretest counseling, one enzyme-linked immunosorbent
assay (ELISA), and post-test counseling on a return visit.
For the 45% of women who give birth in states with low
seroprevalence rates (less than one HIV-infected pregnant
woman per 1000 live births), we assumed the costs of counseling seronegative women to be subsumed into routine prenatal care. Therefore, we assigned a cost of $6 per person
(the cost of the ELISA) for seronegative women in these
states.'7 Thus, the overall national cost estimate for HIV
counseling and testing of seronegative women was $19.50
per person. For seropositive women, the cost of HIV counseling and testing was $103, which included additional costs
for post-test counseling and confirmatory tests (ELISA and
Western blot).'7
We also assumed that all HIV-infected pregnant women
receiving prenatal care in the first or second trimester would
be offered ZDV treatment, regardless oftheir CD4+ T-lymphocyte counts or prior use of ZDV. Women who experienced fetal loss, who chose to terminate their pregnancies,
or who entered prenatal care during the third trimester or
later were excluded.
ZDVtreatment costs. Average duration of ZDV therapy used
in the ACTG Protocol 0764 and average weights for a
woman (50 kilograms) and newborn infant (4 kilograms)
were used in calculating the cost of the ZDV regimen. The
defined regimen involved oral ZDV for infected women
during pregnancy (100 milligrams per dose multiplied by 5
doses per day multiplied by 12 weeks [420 100-milligram
capsules]); intravenous ZDV for women during labor and
delivery (2 milligrams per kilogram plus 1 milligram per
kilogram per hour for 12 hours [700 milligrams ZDV]); and
oral ZDV for HIV-exposed newborns (2 milligrams per
July/August 1996 * Volume I I I

kilogram per dose multiplied by 4 doses per day multiplied
by 6 weeks [134 cubic centimeters of syrup]).
We contacted five principal investigators of the original
ACTG Protocol 076 (from geographically representative
areas) to obtain the current wholesale costs of the recommended preparations of ZDV from their hospital pharmacies. The following average ZDV treatment costs per person
were used: (a) $551 for maternal treatment during pregnancy; (b) $46 for maternal treatment during labor and
delivery; and (c) $17 for newborn treatment. Costs involved
in administering intravenous ZDV were not included.
Using standard hospital laboratory cost data, we estimated the costs for laboratory testing during ZDV therapy
(two 20-test chemistry profiles for the mother, two complete blood counts (CBC) for the mother, and one CBC for
the infant5 as follows: (a) $35 for each chemistry profile; and
(b) $21 for each CBC.

Costs ofmedical care treatment for HIV-infected infants.
We adapted reported annual costs for HIV-infected children8 to estimate lifetime costs for a perinatally infected
child (Table 1). Based on information from the revised classification system for HIV infection in children'8 as well as
reported symptomatic disease progression,19 the following
average profile was developed for a child infected at birth:
no symptoms in the first 9 months of life followed by mild
HIV symptoms in months 10 to 13, moderate symptoms in
months 14 to 57, and AIDS development at months 58 to
113 (average life span, 113 months).
Table 1. Annual and lifetime medical costs for
perinatally infected children
SmPtoms
Year

by age

Undiscounted

5% discounted

Of*V

in monthe'

cost

costs

I......
2......
3......

4......
5......
6.......
7.......
8.......
9.......
10 ......
Total ....

1-9, none;
10-12, mild HIV
13, mild; 14-24,
moderate HIV
25-36, moderate HIV
37-48, moderate HIV
49-57, moderate HIV;
58-60, AIDS
61-72, AIDS
73-84, AIDS
85-96, AIDS
97-108, AIDS
109-113,AIDS

$ 1,759

$ 1,675

11,337
11,728
11,728

10,283
10,131
9,648

18,278
37,928
37,928
37,928
37,928
15,803
222,344

14,321
28,302
26,955
25,671
24,449
9,702
161,137

'See references 18, 19.
bMedical costs for treatment of HIV infection before development of AIDS: $9382
per year = $782 per month x 0.75 = $586.38 per month (mild); $782 x 1.25 =
$977.29 per month (moderate). Medical costs for treatment of AIDS: $37,928 per
year = $3,161 per month. See reference 8.
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Because no data exist to differentiate between costs for
children with mild versus moderate symptomatic HIV disease, the following percentages were used: 75% of reported
monthly medical costs for mild-symptom months and 125%
for moderate-symptom months. Using a discount rate of
5%, we estimated the present value of lifetime medical care
treatment costs for one perinatally infected infant and
determined that the medical care costs-saved from preventing one pediatric HIV infection were $161,137.

Assumptions affecting outcomes. The following assumptions were made for the base model: (a) 78% of pregnant
women offered HIV counseling and testing will accept;12°
(b) 68% of HIV-infected women identified through such
screening who are offered ZDV treatment will accept and
complete the first treatment component (oral ZDV during
pregnancy);22 (c) perinatal HIV transmission rates were 8%
with the complete (maternal and infant) ZDV regimen4,
25% with no ZDV4, and 16.5% with maternal oral ZDV
during pregnancy and either maternal intravenous ZDV
during labor and delivery or oral ZDV for the infant (based
on evidence that some reduction in transmission can occur
without completion of all three components of the protocol;23,2 (d) ZDV efficacy in women with CD4+ T-lymphocyte counts more than 200 cells per milliliter or with prior
ZDV therapy was the same as that for women with higher
CD4+ counts and no previous ZDV therapy; and (e) the
proportion of patients completing all components of the
ZDV regimen (pregnancy, labor and delivery, neonatal) was
the same as that observed in ACTG Protocol 076: 84.5% of
women who completed oral ZDV during pregnancy
received intravenous ZDV during labor and delivery, and
71.4% of infants born to women who completed oral ZDV
during pregnancy received the oral ZDV newborn regimen.4
The assumptions from the base model were varied as
follows: (a) in the no partial effect model, the perinatal
transmission rate was 25% unless all three components of
the ZDV regimen were completed, and (b) in the complete
treatment model, all eligible women and infants completed

all three ZDV treatment components and the transmission
rate was 8%.
Four sensitivity analyses were developed on the base
model only. First, because maternal HIV seroprevalence
rates among states vary from more than 5 per 1000 (New
York) to less than 0.1 per 1000 (Utah), this rate was varied
from the national average of 1.7 per 1000. Next, the proportion of women who accept HIV counseling and testing was
varied upward from the base case of 78%. Third, the proportion of women who receive ZDV treatment was varied
upward from the base case of 68%. Finally, the lifetime cost
of medical treatment for a perinatally infected infant was
varied up and down from the base-case value, since the only
published estimate of pediatric lifetime medical costs8 is not
based upon age-specific cost data.

Results
Without the intervention, 1750 HIV-infected infants
would require treatment (7000 births annually to HIVinfected women, with a 25% perinatal transmission rate).
Using the present value of lifetime medical treatment costs
of $161,137 per infant, the total cost of treating these children was $282 million.
In the base model, the intervention would prevent 656
perinatally transmitted HIV infections (Table 2), resulting
in medical care cost savings of $105.6 million (calculated
from Table 3 as $282 million without the intervention less
$176.4 million with the intervention). When these medical
care cost savings are subtracted from the cost of the intervention ($65.1 million for HIV counseling and testing plus
$2.5 million for the complete ZDV treatment regimen), the
net cost of the intervention is -$38.1 million. Thus, the
intervention is cost-saving.
In the no partial effect model, the costs to provide HIV
counseling and testing and ZDV treatment were the same
as in the base model, but only 574 infections were prevented
(Tables 2 and 3). This resulted in a cost saving of $24.9
million.

Table 2. Number of HIV-infected infants resulting from intervention effects
Toed
Mother
not tested&

Fo6e4neuti
tet resukW

Base case.................
No partial effectf...........

343.3

Complete treatment

343.3

2.8
2.8
2.8

Model

........

343.3

Partal ZDV
treotmeDnt

Ful ZDV

bftted

Infp cone

bDthnenfI

-itu

preetd

396.6

159.1

192.6

1094.4

655.6

396.6

241.0

192.6

1176.3

396.6

742.7

573.7
1007.3

No ZDV

(mother or kovn4

'25% transmission rate.
b16.5% transmission rate [50% reduction - includes maternal ZDV during pregnancy plus either maternal ZDV during labor and delivery or neonatal ZDV].
'8% transmission rate.
dinfected infants without intervention (1750) minus total infected infants.
"Assumes parameters of ACTG protocol 076 and 50% efficacy from partial ZDV treatment.
'Assumes parameters of ACTG protocol 076 and no effect from partial ZDV treatment
'Assumes parameters of ACTG protocol 076 and that women eligible for ZDV complete all components.
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Table 3. Cost and effectiveness of intervention for pregnant women in the United States
Medkol costs
and test

Model

Base caseb .................$ 65,068,921
No partial effectc ........... 65,068,921
Complete treatmend ........ 65,068,921

infec1o

Wnr

W*bout

Medkal

kbreno

iktnentien

coase vv&

Net cos

prvented

$2,478,709

$176,346,305

$281,989,750

$105,643,445

-$38,095,816

2,478,709
3,704,444

189,552,758
119,679,701

281,989,759
281,989,759

92,436,992
162,310,049

-24,889,363
-93,536,684

655.6
573.7
1007.3

Counseln
ZDV

aten

'Negative net costs represent cost savings.
bAssumes parameters of ACTG protocol 076 and 50% efficacy from partial ZDV treatment.
'Assumes parameters of ACTG protocol 076 and no effect from partial ZDV treatment.
dAssumes parameters of ACTG protocol 076 and that women eligible for ZDV complete all components.
*Medical costs without intervention minus costs with intervention.
'Cost of counseling, testing, and ZDV treatment minus medical costs saved.

In the complete treatment model, the counseling and
testing costs were also the same as in the base model, but the
ZDV treatment costs were higher ($3.7 million compared
with $2.5 million), since all eligible HIV-infected women
and -exposed infants received the complete ZDV treatment
regimen (Table 3). In this model, a larger number of infections were prevented (1007), resulting in a greater medical
care cost-saving ($162.3 million) and a net cost-saving of
$93.5 million.
Table 4 shows the effect of varying rates of maternal
HIV seroprevalence on the number of pediatric infections
prevented and the net cost of the intervention. The net cost
ranged from $58.6 million at a seroprevalence rate of 0.1 per
1000 to a cost-saving of $235.6 million at a seroprevalence
rate of 5 per 1000. The intervention became cost-saving at
an HIV seroprevalence rate of 1.1 per 1000.
The effects of changing other assumptions in the sensitivity analysis of the base model are also shown in Table 4.
Increasing the proportion of women who receive counseling
and testing during pregnancy had only a modest effect on
the net cost of the intervention. The cost savings increased
from $38.1 million with a 78% acceptance rate (the base
model) to $42.7 million with a 94% acceptance rate. However, as the proportion of HIV-infected women receiving
ZDV treatment increased from 68% (the base model) to
95%, the cost savings of the intervention increased substantially from $38.1 million to $68.5 million. Changes in the
estimate of the lifetime medical costs of treating a perinatally HIV-infected child had a large impact on the net cost
of the intervention. The cost savings varied from $14.4 million with a treatment cost of $125,000 per infected child to
$80 million with a cost of $225,000 per child.

Discussion
We calculated the annual cost of HIV counseling and
voluntary testing for pregnant women and the cost of ZDV
treatment for HIV-infected women and their infants. These
intervention costs were compared with the medical care
costs saved from the resulting reduction in the number of
July/August 1996
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pediatric HIV infections. For the United States, with a
maternal HIV seroprevalence of 1.71 per 1000 births, the
cost-savings of the intervention ranged from $24.9 million
to $93.5 million, depending on the assumptions made
regarding the effectiveness of ZDV and the participation of
HIV-infected pregnant women (Table 3). Thus, the intervention was cost-saving for both the base and the alternative
models. Sensitivity analyses of four major input parameters
showed that the intervention remained cost-saving under
most of our alternative assumptions (Table 4).
HIV counseling and testing of seronegative women
constituted a primary cost component of the intervention,
accounting for 95% of the total in the base case. The model
was very sensitive to assumptions made about counseling
costs. The time allotted for a client-based14'15 HIV counseling session will depend on the client's risk, and the cost will
vary according to session length. There are no data available
on the cost of HIV counseling in the private sector and very
little on cost in the public sector.15'17 The purpose of counseling associated with HIV testing has gradually changed as
the epidemic evolved25 and may differ considerably among
testing sites. In addition, the cost effectiveness of a HIV
counseling and testing strategy has been shown to be
dependent on the inherent goal of testing.17 Therefore, to
determine the cost and cost-effectiveness of implementing
HIV screening of pregnant women and ZDV treatment for
infected women and infants more precisely, it is imperative
to clarify the purpose, time allotted, and cost for counseling
associated with HIV testing in this setting and to define
precisely the goal of HIV counseling and voluntary testing
of pregnant women.
The number of children who will be perinatally infected
and, thus, the total costs of pediatric HIV treatment as estimated by our model are affected both by the number of
women who are not tested and the proportion who receive
no or partial ZDV treatment. Data are needed on the independent effect of each component (pregnancy, labor and
delivery, neonatal) of the ZDV regimen.
The overall cost-effectiveness of the intervention varies
according to maternal HIV seroprevalence. In most geoPublic Health
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Table 4. Effect of modifying model assumptions on the
net cost of the intervention
Modificaions

Net cost

Maternal seroprevalence
0.00010 .................................
0.00100 .................................
0.00170 .................................
0.00200 .................................
0.00300 .................................
0.00500 .................................

-38,095,816
-55,486,746
-115,523,387
-235,611,260

Proportion of pregnant women
accepting HIV counseling and testing
0.78 ....................................
0.82 ....................................
0.86 ....................................
0.90 ....................................
0.94 ....................................

-38,095,816
-39,242,885
-40,389,955
-41,537,024
-42,684,093

Proportion of HIV-infected women
accepting ZDV treatment during pregnancy
0.68 ....................................
0.70 ....................................
0.75 ....................................
0.80 ....................................
0.85 ....................................
0.90 ....................................
0.95 ....................................

-38,095,816
-40,350,747
-45,988,075
-51,625,403
-57,262,731
-62,900,058
-68,537,386

$58,590,167
4,564,485

Lifetime medical care treatment costs
for a perinatally infected child

$125,000 .................................
140,000 .................................
165,000 .......................
180,000 .................................
195,000 .................................
210,000 .................................
225,000 .................................
..........

-14,403,944
-24,238,133
-40,628,448
-50,462,636
-60,296,825
-70,131,014
-79,965,203

graphic regions, the intervention was cost-saving except for
areas with very low HIV seroprevalence rates. The intervention was also found to be cost-saving when a slightly different model and locally determined costs were analyzed in an
urban setting.26
A similar cost-effectiveness analysis for the prevention
of perinatally transmitted hepatitis B virus (HBV)
infection27 estimated that maternal screening and infant
treatment would save more than $100 million annually if
indirect costs from lost productivity and premature death
were included. Our analysis was far more conservative, using
only the direct costs of medical treatment for pediatric HIV
infections and no indirect costs. The national maternal
HBV seroprevalence is 2 per 1000, which is very similar to
maternal HIV seroprevalence, and prenatal HBV screening
is an accepted public health practice. In comparison, prena440 Public Health Reports

tal HIV screening is substantially more cost-effective and
compares favorably with other life-saving interventions.8
This model may underestimate costs since it excluded
those associated with a visit by a health-care professional to
HIV-infected pregnant women identified through screening
to explain the ZDV treatment regimen, obtain informed
consent, explain the protocol, and prescribe the ZDV. Also,
our ZDV treatment costs did not include administration
costs or costs associated with additional visits by health-care
professionals or complications resulting from therapy.
Benefits from HIV counseling of pregnant women that
were not included in this analysis, such as behavior changes
that can reduce HIV transmission to the sexual or needlesharing partners of infected women, have been estimated to
exceed the benefits for infants.9,10 We limited our analysis to
prevention of perinatal HIV transmission and, therefore,
have underestimated the total benefits of the intervention.
We did not attempt to address the human costs of HIV
infection such as the emotional and cost burden of infection
for the patient as well as the patient's family, friends, and
care givers. Nor did we address the indirect costs such as
those associated with orphaned children and years of productive labor lost due to illness and premature death. The
model focuses on the first year of the intervention only. Any
changes in behavior or maternal seroprevalence resulting
from the intervention are not included in the analysis.
Finally, our model does not address any, as yet unknown,
long-term detrimental health effects associated with ZDV
given to uninfected children.
A reduction in the rate of perinatal HIV transmission
through ZDV treatment represents a major breakthrough
for HIV prevention. Translating the findings of the ACTG
Protocol 076 into public health interventions that can maximize the opportunity for treatment of the 7000 HIVinfected U.S. women who give birth each year requires a
number of systematic steps. The first steps of developing
public health policies in response to the research findings
have been taken. The ability to implement these policies
into national and local prevention interventions depends in
part on their cost. This analysis demonstrates a cost-savings
to society when the costs of the intervention are compared
with the medical care costs saved by reducing the number of
pediatric HIV infections. These findings strongly support
implementation of the PHS recommendations for the prevention of perinatal HIV infection.
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